Whanin Pharm (016580.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7016580003

Price
10,770.00 KRW
Market cap
199.07 bn KRW
P/E (2025)
12.89
P/S (2025)
0.78
Dividend yield
2.79 %
Net margin
5.33 %
Return on equity (ROE)
3.23 %
Return on assets (ROA)
2.84 %

Whanin Pharm financials

Fiscal year20242025
Revenue259.60 bn KRW255.21 bn KRW
Gross profit93.78 bn KRW87.10 bn KRW
Operating income21.50 bn KRW13.02 bn KRW
EBIT26.97 bn KRW14.95 bn KRW
Net income23.38 bn KRW13.60 bn KRW
Diluted EPS – continuing operations1,531.45 KRW835.75 KRW

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Whanin Pharm

Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, antiseizure, antidepressant, antipsychotic, central nervous system stimulant, anti-dementia, nootropic, alcohol use disorder, anti-Parkinson, multivitamin, external preparation, medical device, and sedative, hypnotic, and autonomic nervous system medications. The company was founded in 1978 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.